Case Study: Novo Nordisk accelerates clinical documentation and drug development with Claude

Novo Nordisk accelerates clinical documentation and drug development with Claude

Novo Nordisk, a global pharmaceutical company, faced significant challenges with the immense regulatory documentation required for drug development. Manual processes for creating clinical study reports were extremely time-consuming, taking months to complete and delaying the delivery of life-changing medicines to patients. The company partnered with the vendor Claude, utilizing their Claude Code product to address this bottleneck.

By building an AI-powered platform called NovoScribe with Claude Code, Novo Nordisk automated the generation of regulatory documents. The solution from Claude slashed the time to produce clinical study documentation from over ten weeks to just ten minutes and achieved a 95% reduction in resources needed for device verification protocols. This dramatically accelerated the company's drug development cycle and allowed them to bring treatments to market faster.

Novo Nordisk

Waheed Jowiya

Digitalization Strategy Director